69 related articles for article (PubMed ID: 1737366)
1. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.
Talpaz M; Chernajovsky Y; Troutman-Worden K; Wetzler M; Kantarjian H; Gutterman JU; Kurzrock R
Cancer Res; 1992 Mar; 52(5):1087-90. PubMed ID: 1737366
[TBL] [Abstract][Full Text] [Related]
2. A possible correlation between interferon-stimulated gene expression and cytogenetic responses in chronic myelogenous leukemia patients treated with alpha-interferon.
Kawakubo K; Ohyashiki K; Ohyashiki JH; Shimamoto T; Fujimura T; Iwama H; Toyama K
Jpn J Clin Oncol; 1996 Apr; 26(2):59-64. PubMed ID: 8609695
[TBL] [Abstract][Full Text] [Related]
3. Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.
Fischer T; Aman J; van der Kuip H; Rudolf G; Peschel C; Aulitzky WE; Huber C
Br J Haematol; 1996 Mar; 92(3):595-603. PubMed ID: 8616023
[TBL] [Abstract][Full Text] [Related]
4. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-alpha treatment.
Clauss IM; Vandenplas B; Wathelet MG; Dorval C; Delforge A; Content J; Stryckmans P; Huez GA
Blood; 1990 Dec; 76(11):2337-42. PubMed ID: 1701667
[TBL] [Abstract][Full Text] [Related]
5. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
Rosenblum MG; Maxwell BL; Talpaz M; Kelleher PJ; McCredie KB; Gutterman JU
Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
[TBL] [Abstract][Full Text] [Related]
6. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
7. Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response.
de Mel WC; Hoffbrand AV; Giles FJ; Goldstone AH; Mehta AB; Ganeshaguru K
Br J Haematol; 1990 Apr; 74(4):452-6. PubMed ID: 2346724
[TBL] [Abstract][Full Text] [Related]
8. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
9. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
[TBL] [Abstract][Full Text] [Related]
10. Several new approaches to improvement of alpha interferon therapy in chronic myelogenous leukaemia.
Asano S; Ogura H; Tani K; Inoue T; Tojo A; Ozawa K
Eur J Cancer; 1991; 27 Suppl 4():S21-5. PubMed ID: 1799469
[TBL] [Abstract][Full Text] [Related]
11. Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts.
Sissolak G; Hoffbrand AV; Mehta AB; Ganeshaguru K
Leukemia; 1992 Nov; 6(11):1155-60. PubMed ID: 1434798
[TBL] [Abstract][Full Text] [Related]
12. Gamma-IFN induced cell adhesion in chronic myelogenous leukemia cells.
Grandér D; Xu B; Wang P; Einhorn S
Leukemia; 1994 Feb; 8(2):299-304. PubMed ID: 7905942
[TBL] [Abstract][Full Text] [Related]
13. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha inducible 2'-5' oligoadenylate synthetase transcripts in lymphoid and myeloid leukemias.
Sissolak G; Hoffbrand AV; Mehta AB; Ganeshaguru K
Leukemia; 1993 May; 7(5):712-6. PubMed ID: 8483323
[TBL] [Abstract][Full Text] [Related]
15. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
18. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
[TBL] [Abstract][Full Text] [Related]
19. Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha.
Henic N; Preudhomme C; Noel M; Lai J; Wetterwald M; Simon M; Fenaux P
Leukemia; 1996 Jan; 10(1):185-6. PubMed ID: 8558928
[No Abstract] [Full Text] [Related]
20. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
